| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
1 Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina; 2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 3 Department of Radiation Sciences, Oncology, University of Umeå, Umeå, Sweden; 4 Department of Urology and Clinical Medicine, Örebro University Hospital, Sweden, and Regional Oncological Center, University Hospital, Uppsala, Sweden; and 5 Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Inflammation has been implicated as an etiological factor in several human cancers. Growing evidence suggests that chronic inflammation may also play a role in the etiology of prostate cancer. Considering that genetic susceptibility is a major risk factor for this disease, we hypothesize that sequence variants in genes that regulate inflammation may modify individual susceptibility to prostate cancer. The lipopolysaccharide receptor Toll-like receptor 4 (TLR4) is a central player in the signaling pathways of the innate immune response to infection by Gram-negative bacteria and is an important candidate inflammatory gene. We performed a systematic genetic analysis of TLR4 sequence variants by evaluating eight single-nucleotide polymorphisms that span the entire gene among 1383 newly diagnosed prostate cancer patients and 780 age- and residence-matched controls in Sweden. We found an association between a sequence variant (11381G/C) in the 3'-untranslated region of the TLR4 gene and prostate cancer risk. The frequency of the variant genotypes (CG or CC) was significantly higher in the patients (24.1%) than in the controls (19.7%; P = 0.02). The frequency of risk genotypes among patients diagnosed before the age of 65 years was even higher (26.3%). Compared with men who had the wild-type genotype of this single-nucleotide polymorphism (GG), those with GC or CC genotypes had a 26% increased risk for prostate cancer (odds ratio, 1.26; 95% confidence interval, 1.011.57) and 39% increased risk increased risk for early onset prostate cancer (before age 65 years; odds ratio, 1.39; 95% confidence interval, 1.021.91). The risk attributable to this variant for prostate cancer in Sweden was estimated to be 4.9%. Although the biological mechanism of the observed association remains to be elucidated, our finding supports a role for a bacteria-associated response pathway, possibly acting via inflammation, in the development of prostate cancer.
This article has been cited by other articles:
![]() |
D. Duggan, S. L. Zheng, M. Knowlton, D. Benitez, L. Dimitrov, F. Wiklund, C. Robbins, S. D. Isaacs, Y. Cheng, G. Li, et al. Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP J Natl Cancer Inst, December 19, 2007; 99(24): 1836 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chen, E. Giovannucci, P. Kraft, R. Lazarus, and D. J. Hunter Association between Toll-Like Receptor Gene Cluster (TLR6, TLR1, and TLR10) and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1982 - 1989. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Awomoyi, P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. G. Blanco, and S. N. Vogel Association of TLR4 Polymorphisms with Symptomatic Respiratory Syncytial Virus Infection in High-Risk Infants and Young Children J. Immunol., September 1, 2007; 179(5): 3171 - 3177. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, F. R. Schumacher, S. J. Plummer, E. Jorgenson, G. Casey, and J. S. Witte trans-Fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant Carcinogenesis, June 1, 2007; 28(6): 1232 - 1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cheng, S. J. Plummer, G. Casey, and J. S. Witte Toll-Like Receptor 4 Genetic Variation and Advanced Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 352 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Merrell, J. M. Ilvesaro, N. Lehtonen, T. Sorsa, B. Gehrs, E. Rosenthal, D. Chen, B. Shackley, K. W. Harris, and K. S. Selander Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity Mol. Cancer Res., July 1, 2006; 4(7): 437 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-X. Zhou, W.-H. Jia, G.-P. Shen, H.-d. Qin, X.-J. Yu, L.-Z. Chen, Q.-S. Feng, Y. Y. Shugart, and Y.-X. Zeng Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 862 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gatti, V. Rivero, R. D. Motrich, and M. Maccioni Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation J. Leukoc. Biol., May 1, 2006; 79(5): 989 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sun, F. Wiklund, F.-C. Hsu, K. Balter, S. L. Zheng, J.-E. Johansson, B. Chang, W. Liu, T. Li, A. R. Turner, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 480 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chen, E. Giovannucci, R. Lazarus, P. Kraft, S. Ketkar, and D. J. Hunter Sequence Variants of Toll-Like Receptor 4 and Susceptibility to Prostate Cancer Cancer Res., December 15, 2005; 65(24): 11771 - 11778. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Bauer, D. Dixon, L. M. DeGraff, H.-Y. Cho, C. R. Walker, A. M. Malkinson, and S. R. Kleeberger Toll-Like Receptor 4 in Butylated Hydroxytoluene-Induced Mouse Pulmonary Inflammation and Tumorigenesis J Natl Cancer Inst, December 7, 2005; 97(23): 1778 - 1781. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Malathi, J. M. Paranjape, E. Bulanova, M. Shim, J. M. Guenther-Johnson, P. W. Faber, T. E. Eling, B. R. G. Williams, and R. H. Silverman A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L PNAS, October 11, 2005; 102(41): 14533 - 14538. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sun, F. Wiklund, S. L. Zheng, B. Chang, K. Balter, L. Li, J.-E. Johansson, G. Li, H.-O. Adami, W. Liu, et al. Sequence Variants in Toll-Like Receptor Gene Cluster (TLR6-TLR1-TLR10) and Prostate Cancer Risk J Natl Cancer Inst, April 6, 2005; 97(7): 525 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Wiklund, B.-A. Jonsson, A. J. Brookes, L. Stromqvist, J. Adolfsson, M. Emanuelsson, H.-O. Adami, K. Augustsson-Balter, and H. Gronberg Genetic Analysis of the RNASEL Gene in Hereditary, Familial, and Sporadic Prostate Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7150 - 7156. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |